Home The Word Brain	My Amedeo FAQ Privacy About
	Hanzi Hunter Learning 500 Chinese characters in 30 days is possible. Abstract • About

Prostate Cancer

Free Subscription 23.03.2026 1 AJR Am J Roentgenol 1 BJU Int 1 BMC Cancer 2 BMC Urol 1 Br J Radiol 1 Endocrinology 1 Eur Radiol 1 Eur Urol 1 Int J Radiat Oncol Biol Phys 4 Int J Urol 2 J Clin Oncol 1 J Magn Reson Imaging 1 J Natl Cancer Inst 1 J Nucl Med 1 J Surg Oncol 1 Nat Rev Urol 1 Oncol Rep 1 Proc Natl Acad Sci U S A 5 Prostate 1 Semin Oncol 2 Urology

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

AJR Am J Roentgenol

1. LEE MH, Pickhardt PJ
   Advancing Clinically Feasible Opportunistic Screening: Use of Attenuation Correction CT From PET/CT for Osteoporosis and Fracture Risk Assessment in Patients With Prostate Cancer.
   AJR Am J Roentgenol. 2026 Mar 18. doi: 10.2214/AJR.26.34830.
   PubMed        
   
   

   
   BJU Int

2. WAGNER MC, Klemm J, Roessler N, Schulz RJ, et al
   Long-term patient-reported outcomes of open urorectal fistula repair after prostate cancer treatment.
   BJU Int. 2026 Mar 13. doi: 10.1111/bju.70233.
   PubMed         Abstract available
   
   

   
   BMC Cancer

3. HAKEM ZADEH F, Shah N, Bird V
   Prostate cancer and CAR-T therapy: a systematic review.
   BMC Cancer. 2026 Mar 14. doi: 10.1186/s12885-026-15703.
   PubMed        
   
   

   
   BMC Urol

4. WU C, Jiao Z, Wu H, Liu X, et al
   A retrospective study comparing multimodal fusion biopsy and conventional cognitive fusion biopsy for diagnosing prostate cancer.
   BMC Urol. 2026 Mar 17. doi: 10.1186/s12894-026-02108.
   PubMed        
   
   
5. OKROSI A, Svarer AP, Rosta G, Wambacher B, et al
   Is MRI/US-guided fusion biopsy ready to replace systematic biopsy in detecting clinically significant prostate carcinoma? - a retrospective study.
   BMC Urol. 2026 Mar 17. doi: 10.1186/s12894-026-02113.
   PubMed        
   
   

   
   Br J Radiol

6. WITHEY SJ, Caglic I, Barrett T
   Prostate MRI in the UK: a survey of current practice by the British Society of Urogenital Radiology.
   Br J Radiol. 2025 Dec 14:tqaf312. doi: 10.1093.
   PubMed         Abstract available
   
   

   
   Endocrinology

7. COOKE M, Elyoussef Y, Abba MC, Kazanietz MG, et al
   Diacylglycerol-Regulated Protein Kinases and Transcriptional Networks in Prostate Cancer.
   Endocrinology. 2026 Mar 16:bqag030. doi: 10.1210.
   PubMed         Abstract available
   
   

   
   Eur Radiol

8. ANDRADE MA, Rodrigues H, Colhado CH, Godinho NJS, et al
   Artificial-intelligence models vs. radiologists in the detection of clinically significant prostate cancer on mpMRI: a meta-analysis.
   Eur Radiol. 2026 Mar 18. doi: 10.1007/s00330-026-12465.
   PubMed         Abstract available
   
   

   
   Eur Urol

9. CHAPIN BF, Smaldone M, Zurita AJ, Wang J, et al
   A Phase 2, Randomized, Controlled Trial of Best Systemic Therapy Versus Best Systemic Therapy with Definitive Treatment of the Primary Tumor in Metastatic Prostate Cancer.
   Eur Urol. 2026 Mar 11:S0302-2838(26)02002-6. doi: 10.1016/j.eururo.2026.
   PubMed         Abstract available
   
   

   
   Int J Radiat Oncol Biol Phys

10. HOWARD TP, Walburn T, Benham G, Chirmade S, et al
    Four-Year Feasibility and Safety Results of a Phase 1/2 Single-Arm Prospective Clinical Trial of Stereotactic Magnetic Resonance-Guided Adaptive Radiation Therapy for Metachronous Oligometastatic Abdominopelvic Lymph Node and Soft Tissue Metastases.
    Int J Radiat Oncol Biol Phys. 2026;124:1404-1410.
    PubMed         Abstract available
    
    

    
    Int J Urol

11. SUGINO A, Miyazawa Y, Nakazawa S, Tsuji Y, et al
    Active Surveillance for Localized Prostate Cancer: A Retrospective Single-Center Study.
    Int J Urol. 2026;33:e70433.
    PubMed         Abstract available
    
    
12. YAEGASHI H, Nakashima K, Miwa S, Miyagi T, et al
    Clinical Validation of the Prostate Health Index for Detecting Clinically Significant Prostate Cancer in a Population-Based Screening Program.
    Int J Urol. 2026;33:e70409.
    PubMed         Abstract available
    
    
13. IWAMOTO H, Hori T, Inaba T, Nakagawa R, et al
    Prognostic Significance of Radiographic Progression at Metastatic Castration-Resistant Prostate Cancer Diagnosis.
    Int J Urol. 2026;33:e70435.
    PubMed         Abstract available
    
    
14. KAZASHI K, Washino S, Saito K, Oshiro H, et al
    Functional and Oncological Outcomes of Novel Anterior, Retzius-Sparing, and Conventional Anterior Approaches in Robot-Assisted Radical Prostatectomy: A Comparative Cohort Study.
    Int J Urol. 2026;33:e70412.
    PubMed         Abstract available
    
    

    
    J Clin Oncol

15. BOLEK H, Urun Y
    Comments on the LUNAR Trial in Oligorecurrent Hormone-Sensitive Prostate Cancer.
    J Clin Oncol. 2026 Mar 18:JCO2502722. doi: 10.1200/JCO-25-02722.
    PubMed        
    
    
16. VALLE LF, Calais J, Kishan AU
    Reply to: Comments on the LUNAR Trial in Oligorecurrent Hormone-Sensitive Prostate Cancer.
    J Clin Oncol. 2026 Mar 18:JCO2600241. doi: 10.1200/JCO-26-00241.
    PubMed        
    
    

    
    J Magn Reson Imaging

17. CHENG H, Lu J, Liu M, Zhang W, et al
    Comparing Radiologist Performance in Diagnosing Clinically Significant Prostate Cancer With Biparametric Versus Size-Selective Diffusion MRI.
    J Magn Reson Imaging. 2026 Mar 15. doi: 10.1002/jmri.70297.
    PubMed         Abstract available
    
    

    
    J Natl Cancer Inst

18. LIU B, Himbert C, Vaselkiv JB, Mcgrath CB, et al
    Healthy dietary patterns and survival among men with prostate cancer.
    J Natl Cancer Inst. 2026 Mar 15:djag071. doi: 10.1093.
    PubMed         Abstract available
    
    

    
    J Nucl Med

19. GOGEBAKAN KC, Kunst N, Ghodsi A, Owens L, et al
    Cost-Effectiveness Analysis of (177)Lu-PSMA-617 Versus Cabazitaxel in Metastatic Castration-Resistant Prostate Cancer from a U.S. Health Care Perspective.
    J Nucl Med. 2026 Mar 19:jnumed.125.271825. doi: 10.2967/jnumed.125.271825.
    PubMed         Abstract available
    
    

    
    J Surg Oncol

20. WU X, Yao W
    Artificial Intelligence Models Integrating Preoperative Prostate MRI and Clinical Parameters for Predicting Extraprostatic Extension: A Systematic Review and Meta-Analysis.
    J Surg Oncol. 2026;133:406-415.
    PubMed         Abstract available
    
    

    
    Nat Rev Urol

21. BALAJI S, Lepor H, Polascik TJ
    How urology can embrace the patient-centric precision focal therapy approach for localized prostate cancer.
    Nat Rev Urol. 2026 Mar 20. doi: 10.1038/s41585-026-01136.
    PubMed        
    
    

    
    Oncol Rep

22. KIM K, Lee J, Choi C, Bae J, et al
    Sphingosine?1?phosphate receptor 1 enhances olfactory receptor 51E1?mediated inhibition of proliferation via Src/JNK signaling in prostate cancer cells.
    Oncol Rep. 2026;55:98.
    PubMed         Abstract available
    
    

    
    Proc Natl Acad Sci U S A

23. ABT ER, Wang L, Varuzhanyan G, Freeland J, et al
    Synthetic lethality between RB-loss and E2F3 inhibition in small cell cancers targeted by pyrimidine synthesis blockade.
    Proc Natl Acad Sci U S A. 2026;123:e2532814123.
    PubMed         Abstract available
    
    

    
    Prostate

24. KING LD, Christie D, Cehic D, Dare W, et al
    A Feasibility Study of the Repurposing of Prazosin to Improve Treatment Outcomes in Men Receiving Radiotherapy for Prostate Cancer (MiniRaP-00).
    Prostate. 2026 Mar 15. doi: 10.1002/pros.70162.
    PubMed         Abstract available
    
    
25. MASUD N, Sanders J, Iczkowski KA, Shah GV, et al
    Exosomal ZFPL1 Identifies Neuroendocrine and Stem Cell-Like Prostate Cancer Subtypes?
    Prostate. 2026 Mar 15. doi: 10.1002/pros.70148.
    PubMed         Abstract available
    
    
26. TSUTSUMI T, Yamazaki S, Matsuda T, Tsujino T, et al
    The Prognostic Significance of Radiographic Progression Without PSA Progression in Patients With Metastatic Hormone-Sensitive Prostate Cancer Treated With First-Line ARPI Therapy.
    Prostate. 2026 Mar 15. doi: 10.1002/pros.70157.
    PubMed         Abstract available
    
    
27. YASUDA Y, Yoshida S, Yajima S, Yamaguchi Y, et al
    Real-World Comparison of Triplet Versus Doublet Therapy in Japanese Patients With High-Volume Metastatic Hormone-Sensitive Prostate Cancer: A Propensity-Weighted Analysis From the YUSHIMA Registry and Exploratory Bayesian Evidence Synthesis.
    Prostate. 2026 Mar 19. doi: 10.1002/pros.70159.
    PubMed         Abstract available
    
    
28. PARK JJ, Tseng CL, Giagtzis A, Kelley MJ, et al
    SPOP Mutations in Veterans With Prostate Cancer and Outcomes With Doublet and Triplet Therapy in De Novo Metastatic Hormone Sensitive Prostate Cancer.
    Prostate. 2026 Mar 19. doi: 10.1002/pros.70161.
    PubMed         Abstract available
    
    

    
    Semin Oncol

29. SCIALPI M, Scalera GB, Scialpi P, Evangelisti A, et al
    Prostate cancer: Evolution of multiparametric MRI PI-RADS v2.1 toward biparametric MRI S-PI-RADS.
    Semin Oncol. 2026 Feb 13:152471. doi: 10.1016/j.seminoncol.2026.152471.
    PubMed        
    
    

    
    Urology

30. SHORE N
    Editorial Comment on "Homologous recombination repair mutations, next-generation sequencing testing, and treatment progression by race among patients with metastatic castration-sensitive prostate cancer".
    Urology. 2026 Mar 11:S0090-4295(26)00167-6. doi: 10.1016/j.urology.2026.
    PubMed        
    
    
31. YILDIZ AK, Gultekin H, Kacan T, Demir DO, et al
    Evaluation of Multifocal Positive Surgical Margin Predictors and Mapping of Positive Surgical Margin Locations in Robot-assisted Radical Prostatectomy.
    Urology. 2026;209:66-71.
    PubMed         Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Prostate Cancer is free of charge. Privacy / Datenschutzerklärung | Imprint / Impressum